Adderall will return to the Canadian market for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) (see alert of
2/09/05 below). The Canadian Product Monograph will be revised to include warnings about the misuse of Adderall and that Adderall generally should not be used in patients with structural cardiac abnormalities.
This information reflects FDA’s preliminary analysis of data
concerning this drug. FDA is considering, but has not reached a
final conclusion about, this information. FDA intends to update this
sheet when additional information or analyses become available.
For complete, up-to-date safety information by the FDA, see MedWatch